Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

This study (DARES) tests whether adding durvalumab (an immunotherapy) plus targeted radiation to standard chemotherapy improves outcomes for patients with extensive-stage small cell lung cancer — an aggressive form of lung cancer that has spread beyond the chest at the time of diagnosis. **You may be eligible if...** - You are 18 or older with confirmed small cell lung cancer with known metastatic disease - You are suitable to receive platinum-based chemotherapy as your first treatment - You have measurable disease on imaging and are in reasonable health (ECOG 0–2) - Any brain metastases are stable and not causing symptoms **You may NOT be eligible if...** - You have already received treatment for small cell lung cancer - You have active autoimmune disease or other conditions that make immunotherapy unsafe - You have uncontrolled or symptomatic brain metastases - You weigh less than 30 kg Talk to your doctor to see if this trial is right for you.